Vanguard Group
MACK

Vanguard Group’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Vanguard Group’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-620,847
Closed -$9.17M – 4520
2024
Q1 		$9.17M Buy
620,847
+11,893
+2% +$167K ﹤0.01% 3009
2023
Q4 		$8.17M Buy
608,954
+8,610
+1% +$109K ﹤0.01% 3066
2023
Q3 		$7.4M Buy
600,344
+43,546
+8% +$527K ﹤0.01% 3069
2023
Q2 		$6.85M Buy
556,798
+98,277
+21% +$1.23M ﹤0.01% 3156
2023
Q1 		$5.64M Sell
458,521
-129,500
-22% -$1.52M ﹤0.01% 3244
2022
Q4 		$6.74M Sell
588,021
-19,783
-3% -$163K ﹤0.01% 3154
2022
Q3 		$2.28M Sell
607,804
-400
-0.1% -$1.85K ﹤0.01% 3692
2022
Q2 		$3.62M Hold
608,204
– – ﹤0.01% 3537
2022
Q1 		$3.85M Sell
608,204
-8,644
-1% -$48.6K ﹤0.01% 3652
2021
Q4 		$2.41M Sell
616,848
-1,761
-0.3% -$7.64K ﹤0.01% 3974
2021
Q3 		$2.99M Hold
618,609
– – ﹤0.01% 3915
2021
Q2 		$3.95M Hold
618,609
– – ﹤0.01% 3709
2021
Q1 		$3.88M Buy
618,609
+27,987
+5% +$200K ﹤0.01% 3657
2020
Q4 		$4.07M Buy
590,622
+87,595
+17% +$432K ﹤0.01% 3447
2020
Q3 		$2.01M Hold
503,027
– – ﹤0.01% 3482
2020
Q2 		$1.68M Hold
503,027
– – ﹤0.01% 3480
2020
Q1 		$1.08M Hold
503,027
– – ﹤0.01% 3467
2019
Q4 		$1.58M Buy
503,027
+8,000
+2% +$32K ﹤0.01% 3515
2019
Q3 		$2.22M Buy
495,027
+15,847
+3% +$79.2K ﹤0.01% 3420
2019
Q2 		$2.28M Buy
479,180
+193,294
+68% +$916K ﹤0.01% 3438
2019
Q1 		$1.56M Buy
285,886
+7,846
+3% +$36.1K ﹤0.01% 3519
2018
Q4 		$844K Sell
278,040
-416,729
-60% -$1.45M ﹤0.01% 3614
2018
Q3 		$2.91M Sell
694,769
-7,906
-1% -$33.3K ﹤0.01% 3409
2018
Q2 		$2.71M Sell
702,675
-57,904
-8% -$384K ﹤0.01% 3407
2018
Q1 		$4.82M Sell
760,579
-70,567
-8% -$584K ﹤0.01% 3168
2017
Q4 		$6.7M Buy
831,146
+54,569
+7% +$509K ﹤0.01% 3016
2017
Q3 		$8.88M Sell
776,577
-88,451
-10% -$930K ﹤0.01% 2867
2017
Q2 		$8.44M Sell
865,028
-439,749
-34% -$8.98M ﹤0.01% 2857
2017
Q1 		$31.6M Buy
1,304,777
+136,101
+12% +$3.41M ﹤0.01% 2215
2016
Q4 		$37.5M Buy
1,168,676
+23,806
+2% +$1.02M ﹤0.01% 2113
2016
Q3 		$57.2M Sell
1,144,870
-151,094
-12% -$6.27M ﹤0.01% 1869
2016
Q2 		$55M Buy
1,295,964
+121,785
+10% +$6.63M ﹤0.01% 1858
2016
Q1 		$77.3M Sell
1,174,179
-136,634
-10% -$7.13M 0.01% 1642
2015
Q4 		$81.5M Buy
1,310,813
+69,474
+6% +$4.89M 0.01% 1601
2015
Q3 		$83.1M Buy
1,241,339
+49,232
+4% +$4.02M 0.01% 1565
2015
Q2 		$116M Buy
1,192,107
+85,440
+8% +$8.13M 0.01% 1422
2015
Q1 		$103M Buy
1,106,667
+265,719
+32% +$22.6M 0.01% 1473
2014
Q4 		$74.8M Buy
840,948
+126,622
+18% +$9.22M 0.01% 1615
2014
Q3 		$49.3M Buy
714,326
+28,420
+4% +$1.52M ﹤0.01% 1794
2014
Q2 		$39.3M Buy
685,906
+16,009
+2% +$813K ﹤0.01% 1947
2014
Q1 		$26.6M Buy
669,897
+36,976
+6% +$1.58M ﹤0.01% 2095
2013
Q4 		$26.6M Buy
632,921
+35,999
+6% +$1.04M ﹤0.01% 2062
2013
Q3 		$17.8M Buy
596,922
+119,085
+25% +$4.17M ﹤0.01% 2154
2013
Q2 		$25.3M Buy
+477,837
New +$20.9M ﹤0.01% 1988

Other funds holding MACK

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
RA
Rise Advisors Rochester, New York $355M AUM 20.51% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Vanguard Group's MACK Position: Q2 2024 in Review

Vanguard Group sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 620,847 shares — an estimated $9.17M sold.

Vanguard Group first reported a position in MACK in Q2 2013 and held it in 44 quarters. The position peaked at $116M in Q2 2015. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.

  • Vanguard Group reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
  • Vanguard Group sold 620,847 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $9.17M.
  • Vanguard Group first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 44 quarters.
  • Vanguard Group's Merrimack Pharmaceuticals, Inc. position peaked at $116M in Q2 2015.
  • 12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.

Based on Vanguard Group's 13F filing for Q2 2024, filed 13 Aug 2024.